Breaking News

Actavis Expands PR Manufacturing Ops

May 29, 2014

To develop solid dosage manufacturing, packing facility at Manati site

Through an agreement with the Puerto Rico Industrial Development Co. (PRIDCo), Actavis is investing $48 million in a solid dosage manufacturing and packing facility at its Manati site and will expand its current hormone production in Fajardo.
The expansion will create as many as 300 new jobs during a three-year period. The company also recently acquired the global operations of Warner Chilcott, including the Manati and Fajardo plants. The investment will allow the company to bring new lines of generic, brand and biosimilar products.
PRIDCo is promoting the expansion with incentives for job creation and infrastructure, as well as other benefits under the Economic Incentives for Development Act.
“This is a significant increase in production and jobs of a company that already is contributing close to $78 million a year to Puerto Rico’s economy, between salaries, income taxes and purchases to suppliers,” said governor García Padilla while visiting the Manati site, on the northern region of PR.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks